Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | February 27, 2026 (Beta Thalassemia & Sickle Cell Disease ISS RFP)
Funding Amounts: No set cap; requests should reflect fair market value and not exceed 30% of an organization's annual budget per year.
Summary: Supports independent medical and patient education/advocacy initiatives in cystic fibrosis, sickle cell disease, type 1 diabetes, and related areas.
Key Information: Applications accepted year-round for most programs; specific RFP windows for some disease areas.